Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004478
Status:
COMPLETED
Last Update Posted:
2008-09-18
First Post:
1999-10-18
Brief Title:
Droxidopa in Treating Patients With Neurogenic Hypotension
Sponsor:
Icahn School of Medicine at Mount Sinai
Organization:
Office of Rare Diseases ORD
Study Overview
Official Title:
Study of Droxidopa in Patients With Neurologic Hypotension
Status:
COMPLETED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Please note that the continuation study can be found at httpclinicaltrialsgovshowNCT00633880
RATIONALE Neurogenic hypotension is a fall in blood pressure that occurs when one moves from a lying down to a standing position or after eating a meal It causes one to feel dizzy light headed and weak Neurogenic hypotension is caused by a problem in the part of the nervous system that controls such functions as heart rate and blood pressure Droxidopa a drug that may increase blood pressure may be an effective treatment for neurogenic hypotension
PURPOSE Clinical trial to study the effectiveness of droxidopa in treating patients who have neurogenic hypotension
RATIONALE Neurogenic hypotension is a fall in blood pressure that occurs when one moves from a lying down to a standing position or after eating a meal It causes one to feel dizzy light headed and weak Neurogenic hypotension is caused by a problem in the part of the nervous system that controls such functions as heart rate and blood pressure Droxidopa a drug that may increase blood pressure may be an effective treatment for neurogenic hypotension
PURPOSE Clinical trial to study the effectiveness of droxidopa in treating patients who have neurogenic hypotension
Detailed Description:
PROTOCOL OUTLINE
Patients receive escalating doses of droxidopa or placebo for 7-14 days Patients undergo blood pressure measurements hourly in both supine and standing positions
Patients receive escalating doses of droxidopa or placebo for 7-14 days Patients undergo blood pressure measurements hourly in both supine and standing positions
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MTS-GCO-98-243-3-NE | None | None | None |